Navigation Links
Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in,Lamellar Ichthyosis

groups at weeks 8 and 12 versus approximately 10% reduction for placebo. Statistically significant differences as compared to placebo were not achieved for the erythema or pruritus scores which were less severe at baseline.

The drug was well-tolerated across both active treatment arms, and there were no reports of drug-related serious adverse events.

"Although we just missed statistical significance for the primary endpoint, we are pleased with these results given the limited number of patients in the study. These results are consistent with data from previous studies of liarozole in this rare debilitating disease," commented Geert Cauwenbergh, Ph.D., Chief Executive Officer of Barrier Therapeutics. "These data provide additional support for the potential efficacy and safety of the class of retinoic acid metabolizing blocking agents (RAMBAs), which inhibit the body from breaking down its own retinoic acid, the active form of vitamin A, a key nutrient for healthy skin. While Barrier has no plans to further develop this product candidate itself, we intend to provide the data to U.S. and European regulatory authorities and to companies focused on orphan drugs."

About Liarozole

Liarozole is a novel compound that belongs to a new class of drugs known as retinoic acid metabolism blocking agents, or RAMBAs. Retinoic acid, also known as vitamin A, is essential for optimal functioning of the skin. In contrast to current synthetic retinoid treatments, which introduce man-made forms of vitamin A into the body, RAMBAs work by slowing the metabolism or degradation of the body's own retinoic acid. This causes the body to maintain higher, potentially therapeutic levels of this natural vitamin in cells of the skin. Based on this mechanism of action and early clinical data, we believe that this class of drugs could be effective in treating skin diseases and conditions, such as congenital ichthyosis, psoriasis, acne and photo-damage, which result from abno
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:9/23/2014)... HARRISBURG, Pa. , Sept. 23, 2014 ... prescription drugs Sat., Sept. 27, as part of National ... anonymous, no questions asked. Take-Back Day is ... Drug Enforcement Administration (DEA), aimed at encouraging the public ... that are prone to abuse and theft. ...
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)... , Sept 23, 2014  Vesselon, Inc. today announced ... of Directors, effective September 15, 2014. Dr. Raths, appointment ... its placement agent to market a private preferred Series ... early stroke treatment. "Jurgen,s deep experience across ... a great asset to Vesselon as we develop our ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... Novavax, Inc. (Nasdaq:,NVAX) today announced that it ... vaccine candidate against Severe Acute Respiratory Syndrome,(SARS). The ... Institutes of Health (NIH) to continue preclinical development ... "Until now, it has been difficult to ...
... Three of Four HUMIRA Patients from CHARM Study in Remission ... ... May 21 Results from an,open-label extension study of two ... patients treated with,HUMIRA(R) (adalimumab) achieved long-term clinical remission and clinical,response, ...
Cached Medicine Technology:Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development 2Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 2Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 3Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 4Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 5Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 6Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission 7
(Date:9/23/2014)... CA (PRWEB) September 23, 2014 Oaksterdam ... Industry Today . In its first post, the University ... growing and changing cannabis industry. , The cannabis industry ... Colorado alone is expecting an 18-month boost of more ... and adult use pot sales. And, the new legal ...
(Date:9/23/2014)... throughout the first year follow a set of ... syllables and first words. However, previous research had ... differ between hearing and deaf infants. Now, University ... primarily motivated by infants, ability to hear their ... who received cochlear implants to help correct their ...
(Date:9/23/2014)... FL (PRWEB) September 23, 2014 ... of the newly renovated Women’s Health Center on ... feet of space, the specially designed center offers ... in East Pasco County. The Women’s Health Center ... pelvic floor health, labor and delivery through The ...
(Date:9/23/2014)... "The primary purpose of the CALL LIGHT CADDY is ... Ca.. "Call lights are often found on the floor, lost ... pole out of the patient's reach. In order to make ... need it, I created this caddy." , She developed the ... within easy reach. The accessory ensures that the call device ...
(Date:9/23/2014)... studies found that FDG-PET technology is less accurate ... regions where infections like histoplasmosis or tuberculosis are ... cancer could lead to unnecessary tests and surgeries ... , Histoplasmosis and other fungal diseases are ... bird droppings and are found in soils. , ...
Breaking Medicine News(10 mins):Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Infant cooing, babbling linked to hearing ability, MU researcher finds 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:Study questions accuracy of lung cancer screens in some geographic regions 2
... the time in emergency rooms , , TUESDAY, Dec. 18 (HealthDay ... someone is having a heart attack, they are mistaken 9.2 ... that minutes matter with these patients and doctors have to ... say researchers from the Minneapolis Heart Institute Foundation. , "Our ...
... three and older in the United States would carry ... the 2008 University of Louisville Grawemeyer Award in Education. ... nations young children, fill a gap for working families, ... boost the economy, award winners Edward Zigler, Walter Gilliam ...
... led by Mayo Clinic have designed a technique that uses ... cells that spread from primary tumors to other parts of ... shows that this technology could be the basis for a ... appeared in the Dec. 9 online issue of Nature Medicine. ...
... inexpensive infection control measures, hospitals around the world could prevent ... TB), according to a new study in The Lancet by ... Wings for its ability to spread and kill rapidly, XDR ... identified in all regions of the world, including the United ...
... for patients with spinal cord injuries can stimulate ... compensatory changes in the brain, say Canadian researchers. ... function and the ability to walk. , A ... the remarkable benefits of rehabilitation training after a ...
... remains America,s No. 1 killer, AHA says , , TUESDAY, ... death rates in the United States are declining, the ... the nation, according to the American Heart Association. , ... for many people, according to the American Heart Association,s ...
Cached Medicine News:Health News:Diagnosis of Heart Attack Can Be Wrong 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 2Health News:Researchers train the immune system to deliver virus that destroys cancer in lab models 3Health News:Simple strategy could prevent half of deadly tuberculosis infections 2Health News:Intensive training post-spinal cord injury can stimulate repair in brain and spinal cord 2Health News:U.S. Heart Disease Death Rates Falling 2Health News:U.S. Heart Disease Death Rates Falling 3
... cage system provides anterior column support for ... from T1 to L5. The system consists ... polymer cages that are stacked to a ... Peek Carbon fiber reinforced polymer material emulates ...
... is an extrudable, moldable bone void filler that ... anywhere in the skeletal system, including extremities, the ... as a temporary scaffolding for new bone formation. ... X-ray, making healing easier to assess. Boneplast kit ...
... CE mark for its synthetic bone substitute Ossatura. ... of a smart material, i.e. a material that ... of events in the musculo-skeletal system that results ... and improved fusion, and reduces in part or ...
... Cerasorb bone regeneration ... beta-tricalcium phosphate composite ensures ... unique spherical structure maximizes ... Permeability is the most ...
Medicine Products: